That is how I interpreted "inactivated" as well, Stoll's choice, which is why I put into question his integrity. You don't pull your application if you whole heartedly believed in the success of the "clean" compound, unless of course the FDA gave him an offer he couldn't refuse. I'm not going to go there anymore however. I am trying to focus on the future.
If a stipulation in trial was presented to COR via the FDA it cetainly would breath new life into CX717 for ADHD as well as have an immediate effect on the SP. I doubt that is even a remote possibility however, but the lack of a reason or formal letter has always been on my mind. Neuro again is probably your best souce for a realistic answer here.
Market Data 
Markets 
AI
